<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mirum Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc</link>
<description>Latest news and press releases for Mirum Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 16 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mirum-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683599bd78dffbe2df105fda.webp</url>
<title>Mirum Pharmaceuticals Inc</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc</link>
</image>
<item>
<title>Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-completes-enrollment-in-phase-3-expand-study-of-livmarlir-maralixibat-in-additional-rare-cholestatic-liver-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-completes-enrollment-in-phase-3-expand-study-of-livmarlir-maralixibat-in-additional-rare-cholestatic-liver-diseases</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 FOSTER CITY,</description>
</item>
<item>
<title>Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-provides-azure-clinical-program-update-for-brelovitug-in-chronic-hepatitis-delta-virus-5</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-provides-azure-clinical-program-update-for-brelovitug-in-chronic-hepatitis-delta-virus-5</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to</description>
</item>
<item>
<title>Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2025-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-fourth-quarter-and-year-end-2025-results-and-provides-business-update</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline</description>
</item>
<item>
<title>Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-to-announce-fourth-quarter-and-year-end-2025-financial-results-and-host-conference-call-on-february-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-to-announce-fourth-quarter-and-year-end-2025-financial-results-and-host-conference-call-on-february-25-2026</guid>
<pubDate>Wed, 18 Feb 2026 21:01:00 GMT</pubDate>
<description>FOSTER CITY, Calif., February 18, 2026--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026</description>
</item>
<item>
<title>Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-health-canada-135100592</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-health-canada-135100592</guid>
<pubDate>Thu, 05 Feb 2026 13:51:00 GMT</pubDate>
<description>TORONTO, February 05, 2026--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome</description>
</item>
<item>
<title>Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-health-canada-130000970</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-health-canada-130000970</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>TORONTO, February 05, 2026--Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis</description>
</item>
<item>
<title>Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-completes-acquisition-bluejay-therapeutics-expanding-global</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-completes-acquisition-bluejay-therapeutics-expanding-global</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio - Topline Phase 3 results</description>
</item>
<item>
<title>Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-preliminary-unaudited-133000409</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-preliminary-unaudited-133000409</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>FOSTER CITY, Calif., January 12, 2026--Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum</description>
</item>
<item>
<title>Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 9, 2026, the Compensation Committee of</description>
</item>
<item>
<title>Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/enthorin-therapeutics-announces-initiation-of-phase-ii-clinical-trial-of-mrm-3379-formerly-ent-3379-for-fragile-x-syndrome-by-licensing-partner-mirum-pharmaceuticals</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/enthorin-therapeutics-announces-initiation-of-phase-ii-clinical-trial-of-mrm-3379-formerly-ent-3379-for-fragile-x-syndrome-by-licensing-partner-mirum-pharmaceuticals</guid>
<pubDate>Fri, 09 Jan 2026 16:55:00 GMT</pubDate>
<description>ESCONDIDO, Calif., January 09, 2026--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).</description>
</item>
<item>
<title>Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-present-44th-annual-210100978</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-present-44th-annual-210100978</guid>
<pubDate>Wed, 07 Jan 2026 21:01:00 GMT</pubDate>
<description>FOSTER CITY, Calif., January 07, 2026--Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</description>
</item>
<item>
<title>Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-additional-private-placement-financing-tcgx-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-additional-private-placement-financing-tcgx-2025-12</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a</description>
</item>
<item>
<title>Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-enters-definitive-agreement-acquire-bluejay-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-enters-definitive-agreement-acquire-bluejay-therapeutics</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly</description>
</item>
<item>
<title>Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-first-patient-enrolled-bloom-phase-2-clinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-first-patient-enrolled-bloom-phase-2-clinical-study</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027 FOSTER CITY,</description>
</item>
<item>
<title>Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-participate-upcoming-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-participate-upcoming-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition,</description>
</item>
<item>
<title>Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-showcases-leadership-liver-disease-innovation-data-livmarlir</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-showcases-leadership-liver-disease-innovation-data-livmarlir</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>New data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases. FOSTER CITY,</description>
</item>
<item>
<title>Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second</description>
</item>
<item>
<title>Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announce-third-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announce-third-quarter-2025-financial-results-and-host</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on</description>
</item>
<item>
<title>Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-enrollment-completion-phase-2b-vistas-study-2025-09</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-announces-enrollment-completion-phase-2b-vistas-study-2025-09</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>- Topline data announcement expected second quarter of 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced</description>
</item>
<item>
<title>Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-second-quarter-200100467</link>
<guid isPermaLink="true">https://6ix.com/company/mirum-pharmaceuticals-inc/news/mirum-pharmaceuticals-reports-second-quarter-200100467</guid>
<pubDate>Wed, 06 Aug 2025 20:01:00 GMT</pubDate>
<description>FOSTER CITY, Calif., August 06, 2025--Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update</description>
</item>
</channel>
</rss>